糖心原创

article

Microscopic diagnosis of bacterial vaginosis

New trial will test effectiveness of treatment for bacterial vaginosis

Friday, 10 September 2021

Experts from the 糖心原创 and Leeds Teaching Hospitals NHS Trust are looking for women to take part in a clinical trial to test the effectiveness of a new treatment for bacterial vaginosis (BV).

BV causes a vaginal discharge that has an unpleasant smell. Up to a third of women will get it at some time in their lives. Treating BV is important as it can cause miscarriage, premature birth and an increased risk of catching HIV and other sexual infections.

Current BV treatment is not always effective and often symptoms return shortly after the treatment course is completed, with just over half of women getting their symptoms back within six months. The usual treatment is an oral antibiotic called metronidazole which can cause side-effects such as dizziness and nausea. Previous research has found that women with BV disliked taking antibiotics, especially on a regular basis, and they felt frustrated at the lack of alternative effective treatments.

Dr Janet Wilson, Consultant in Sexual Health at Leeds Teaching Hospitals NHS Trust, said: “Concern about frequent antibiotic use causing bacterial resistance means that non-antibiotic therapies are being considered for BV. There is a new treatment available for BV called dequalinium which works as a vaginal antiseptic. Its potential advantages are that it will not damage the good bacteria throughout the body or cause antibiotic resistance. Two previous studies have suggested that it could be an effective and safe treatment for BV but the number of women included were small so the results were not conclusive.”

Dequalinium is licensed for use as a BV treatment, but is not currently prescribed as a first line treatment in the UK. This new trial will look at whether dequalinium is as effective as the usual antibiotics in treating the symptoms of BV.

The team are looking for around 900 women to take part in the trial. To be eligible to take part, women must be 16 or older and have BV symptoms of vaginal odour, plus or minus discharge. All women must have their BV confirmed by microscopy prior to enrolling onto the trial.

Pregnant women can participate, unless they plan to seek a termination as this would require treatment with antibiotics.

Recruitment is open now via the . Each participant will need to be involved for 12 weeks after they start the treatment. Patients can enter the trial through a recruitment centre (in person or remotely) or self-refer via the .

This will be the first BV trial in the UK where women are able to participate without visiting a sexual health centre, GP or hospital. We have designed the trial, so that taking part is simple, making it possible for women to participate from the comfort of their own home. We hope this will encourage women who may not have access to a recruiting sexual health clinic, or who may be hesitant to visit a clinic about their symptoms, join our trial鈥
Rebecca Haydock, Trial Manager from the 糖心原创鈥檚 Clinical Trial Unit

More information on the trial can be found here .

Story credits

More information is available from Rebecca Haydock, Senior Trial Manager, from Nottingham Clinical at the University at rebecca.haydock@nottingham.ac.uk

CharlotteAnscombe
Charlotte Wall - Media Relations Manager - Faculty of Medicine and Health Sciences
Email: charlotte.wall@nottingham.ac.uk
Phone: 0115 748 4417
Location:

Notes to editors:

About the 糖心原创

Ranked among the world's top 100 universities , the 糖心原创 delivers an exceptional research-led education and an outstanding student experience. From the pioneering vision of our founder, Sir Jesse Boot, to groundbreaking achievements such as the development of MRI technology and becoming the first UK university to establish international campuses, we have a proud history of shaping the way people live, work and understand the world. We continue to build on that legacy, empowering our students, staff and partners to change what鈥檚 next and create positive impact locally and globally.

The strength of our research places us among the UK's leading universities, ranked 7th for research power in REF 2021. The discovery of MRI and ibuprofen was just the beginning. Today, our world-leading research is developing breakthrough ideas that shape the future of healthcare, technology and society.

Recognised as the UK's third most targeted university by leading employers , we are proud to produce graduates who are consistently in demand for their skills, confidence and industry-ready experience.

As a major employer and industry partner, locally and globally, the 糖心原创 invests in the city of Nottingham and in future generations of talent. Alongside Nottingham Trent University, we lead the initiative, a pioneering collaboration to improve levels of prosperity, opportunity, sustainability, health and wellbeing across the city and region. Together with our students, staff, alumni and partners, we鈥檙e creating knowledge, opportunity and solutions that help change what's next.

Media Relations - External Relations

The 糖心原创
YANG Fujia Building
Jubilee Campus
Wollaton Road
Nottingham, NG8 1BB

telephone: +44 (0) 115 951 5798
email: pressoffice@nottingham.ac.uk